MoonLake - Rasio total nilai perusahaan marang pendapatan MLTX

MoonLake (MLTX) - logo korporat

The change in the enterprise value-to-revenue ratio clearly demonstrates the market valuation of MoonLake Immunotherapeutics (MLTX), where 0.00 determines the current status of the parameter. The company's revenues are based on the market launch of innovative sonelokimab nanobodies. High loyalty among the staff of immunologists supports the pace of development, which is critical for successfully passing clinical trials and subsequent sales of the drug to patients with severe inflammation.

MLTX MoonLake Immunotherapeutics: Rasio nilai perusahaan marang pendapatan ing interval 23.11.2025 - 20.11.2026

MLTX (moonlaketx.com): rincian analitis lan laporan miturut indikator

- indikator dhuwit lan arus kas:
Analisis wiwitan perusahaan:MLTX, moonlaketx.com
Produk asil prodhuksi MoonLake Immunotherapeutics

The investment attractiveness of MoonLake Immunotherapeutics (MLTX) is based on the potential for premium pricing of sonelokimab, which creates a foundation for exponential growth in future cash flows. This metric compares the enterprise value (EV), including debt, to current sales volume, reflecting the market's revaluation of every dollar of revenue. By analyzing the change in the company's EV-to-revenue ratio, an investor can assess the asset's fundamental margin of safety prior to the drug's commercialization.

Analisis pesaing

ASND: Rasio nilai perusahaan marang pendapatan|MDGL: Multiplikator EV/Sales|CORT - Rasio total nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan Rhythm Corp|Akero Corp (AKRO) - Rasio total nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan metsera.com (MTSR)|Nilai perusahaan marang pendapatan Crinetics Pharmaceuticals CRNX|Rasio nilai perusahaan marang pendapatan NewAmsterdam Pharma N.V. NAMS|Rasio total nilai perusahaan marang pendapatan Soleno Therapeutics Inc (SLNO)|FOLD - Rasio nilai perusahaan marang pendapatan|ETNB: Rasio nilai perusahaan marang pendapatan|AGIO: Multiplikator EV/Sales|Structure Therapeutics Inc. - Nilai bisnis marang pendapatan|MDXG (MiMedx Corp) - Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Rezolute Inc RZLT|Multiplikator EV/Sales LXRX|Rasio total nilai perusahaan marang pendapatan MBX Corp|Altimmune Pharma - Nilai perusahaan marang pendapatan|Multiplikator EV/Sales aardvarktherapeutics.com AARD|SGMT: Nilai perusahaan marang pendapatan|Nilai bisnis marang pendapatan BIOA (BioAge Labs)|BMEA: Multiplikator EV/Sales|QNCX: Koefisien nilai perusahaan marang pendapatan|GUTS (Fractyl Health, Inc.) - Multiplikator EV/Sales|Multiplikator EV/Sales vtvtherapeutics.com|Nilai perusahaan marang pendapatan ATPC (Agape ATP Corp)|Rasio total nilai perusahaan marang pendapatan Pluristem Therapeutics|Rasio nilai perusahaan marang pendapatan synlogictx.com SYBX|LPCN: Rasio nilai perusahaan marang pendapatan|MTNB - Rasio nilai perusahaan marang pendapatan|Spruce Biosciences, Inc. (SPRB) - Nilai perusahaan marang pendapatan|GLTO: Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - Multiplikator EV/Sales|Organovo Corp (ONVO) - Rasio total nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan Radius Recycling (RDUS)